v3.26.1
INTERIM CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Operating expenses:        
Research and development, net $ 963 $ 1,120 $ 1,725 $ 2,424
General and administrative 2,650 1,453 3,934 3,238
Operating loss (3,613) (2,573) (5,659) (5,662)
Financial income (expense), net (242) (330) (323) (284)
Gain (loss) on change in fair value of Warrants liability       179
Net loss $ (3,855) $ (2,903) $ (5,982) $ (5,767)
Basic net loss per share from continuing operations (in dollars per share) $ (0.35) $ (0.34) $ (0.54) $ (0.77)
Diluted net loss per share from continuing operations (in dollars per share) $ (0.35) $ (0.34) $ (0.54) $ (0.77)
Weighted average number of shares outstanding used in computing basic net loss per share (in shares) 11,034,775 8,620,400 11,034,775 7,487,495
Weighted average number of shares outstanding used in computing diluted net loss per share (in shares) 11,034,775 8,620,400 11,034,775 7,487,495